임신과 정신약물(I): 정신약물이 태아에게 미치는 영향

키워드

참고문헌 (95)

1. Sadock BJ, "Kaplan & Sadocks Synopsis of Psychiatry", pp.975~979 (2003), Philadelphia: Lippincott Williams & Wilkins
2. "Therapeutic Guidelines Ltd Therapeutic Guidelines: Psychotropic: Psychotropic" (2003), North Melbourne: Therapeutic Guidelines Ltd
3. Frank JB, "Womens mental health in primary care. Depression, anxiety, somatization, eating disorders, and substance abuse", 82, pp.359~389 (1998)
4. Grof P, "Protective effect of pregnancy in women with lithium-responsive bipolar disorder", 61, pp.319~ (2000)
5. Evans J, "Cohort study of depressed mood during pregnancy and after childbirth", 323, pp.257~260 (2001)
6. Eberhard-Gran M, "Depression during pregnancy and after delivery: a repeated measurement study", 25, pp.15~21 (2004)
7. Viguera AC, "Risk of recurrence of bipolar disorder in pregnant and nonpregnant women discontinuing lithium maintenance", 157, pp.179~184 (2000)
8. Brockington I, "Postpartum psychiatric disorders", 363, pp.303~310 (2004)
9. Miller LJ, "Sexuality, reproduction, and family planning in women with schizophrenia", 23, pp.623~625 (1997)
10. McKenna K, "Significant changes in antipsychotic drug use during pregnancy", 46, pp.446~ (2004)
11. Bonari L, "Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making", 8, pp.214~220 (2005)
12. Viguera AC, "Managing bipolar disorder during pregnancy: weighing the risks and benefits", 47, pp.42636~ (2002)
13. Howard L, "Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis", 329, pp.9334~ (2004)
14. Macara LM, "Identifying fetal abnormalities" (2000), London: BMJ Books
15. Gilstrap LC, "Drugs and pregnancy" (1998), Toronto: Chapman and Hall
16. Trixler M, "Antipsychotic use in pregnancy. What are the best treatment options?", 16, pp.40310~ (1997)
17. Cordero JF, "Drug exposure during pregnancy", pp.418~28
18. "content and format for labeling for human prescription drugs", pp.37434~67
19. Altshuler LL, "Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines", 153, pp.592~606 (1996)
20. Slone D, "Antenatal exposure to the phenothiazines in relation to congenital malformations", pp.486~8
21. Wilson DR, "New-onset diabetes and ketoacidosis with atypical antipsychotics", 59, pp.1~6 (2003)
22. Di Michele V, "Clozapine and lorazepam administration in pregnancy", 11, pp.214~ (1996)
23. Stoner SC, "Clozapine use in two full-term pregnancies", 58, pp.364~365 (1997)
24. Dickson RA, "Pregnancy of a patient treated with clozapine", 49, pp.10813~ (1998)
25. Nguyen HN, "Clozapine and pregnancy", 29, pp.11924~ (2003)
26. Vavrusova L, "Clozapine administration during pregnancy", 94, pp.282~285 (1998)
27. Goldstein DJ, "Olanzapine-exposed pregnancies and lactation: early experience", 20, pp.399~403 (2000)
28. Mendhekar DN, "Olanzapine and pregnancy", 35, pp.122~123 (2002)
29. Nagy A, "Olanzapine and pregnancy", 142, pp.137~138 (2001)
30. Kirchheiner J, "Healthy outcome under olanzapine treatment in a pregnant woman", 33, pp.7880~ (2000)
31. McKenna K, "Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study", 66, pp.444~449 (2005)
32. Ernst LC, "The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics", 63, pp.42~55 (2002)
33. Gati A, "Pregnancy and atypical antipsychotics", 11, pp.S247~
34. Levinson AJ, "Pregnancy outcome in women receiving atypical antipsychotic drugs: A prospective, multicentre, controlled study", 60, pp.361~ (2003)
35. "Risperdal product information Physicians Desk Reference Montvale", pp.1580~1584 (2001), NJ:Medical Economics Company, Inc
36. SW Kim. KM Kim. J.M Kim. IS Shin, "Use of long-acting injectable risperidone before and throughout preganancy in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry in press
37. Rosengarten H, "Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats", 72, pp.574~579 (2002)
38. S, "Gentile Clinical utilization of atypical antipsychotics in pregnancy and lactation Ann Phamacother", 38, pp.1265~1271 (2004)
39. Bazier S, "Psychotropic drug directory 2005:the professionals pocket handbook and aide memoire", pp.236~250 (2005), Wilts: Mark Allen Publishing Ltd
40. "Product information Seroquel, Wilmington" (2006), AstraZeneca Pharmaceuticals LP
41. Tnyi T, "Quetiapine and pregnancy", 159, pp.674~ (2002)
42. Taylor TM, "Safety of quetiapine during pregnanc", 160, pp.588~589 (2003)
43. "Abilify (aripiprazole)", pp.1156731B9~1158751B9 (2006), Otsuka Phamaceutical Co.Ltd
44. Weinstein MR, "The International register of Lithium babies", pp.94~100
45. Schou M, "Lithium ingestion by children breast-fed by women on lithium treatment"
46. Edmonds LD, "Ebstein？s anomaly and maternal lithium exposure during pregnancy"
47. Jacobson SJ, "Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester"
48. Cohen LS, "A reevaluation of risk of in utero exposure to lithium"
49. Pearson KH, "Practical guidelines for the treatment of psychiatric disorders during pregnancy", pp.115~123 (2002), Philadelphia: Lippincott, Williams and Wilkins
50. Yonkers KA, "Lithium during pregnancy: drug effects and therapeutic implications", 4, pp.261~269 (1998)
51. Llewellyn A, "The use of lithium and management of women with bipolar disorder during pregnancy and lactation", 59, pp.57~64 (1998)
52. Schou M, "What happened later to the lithium babies A follow-up study of children born without malformations"
53. Crawford P, "Best practice guidelines for the management women with epilepsy", 8, pp.20117~ (1999), The Women with Epilepsy Guidelines Development Group
54. Fried S, "Malformation rates in children of women with untreated epilepsy: a meta-analysis", 27, pp.197202~ (2004)
55. "Teratogenic effects of antiepileptic drugs implications for the management of epilepsy in women of childbearing age", pp.4~
56. Rosa FW, "Spina bifida in infants of women treated with carbamazepine during pregnancy", pp.674~7
57. Jones KL, "Pattern of malformations in the children of women treated with carbamazepine during pregnancy", pp.1661~9
58. American Academy of Pediatrics, "Use of psychoactive medications during pregnancy and possible effects on the fetus and newborn", 105, pp.880~887 (2000), Committee on Drugs
59. Iqbal MM, "Effects of antimanic mood-stabilizing drugs in fetuses, neonates and nursing infants", 94, pp.30422~ (2001)
60. Frey B, "Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breastfeeding"
61. Mor N, "Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy", pp.66~
62. Keller, "Teratologic Effects of Carbamazepine" (1989)
63. Kennedy D, "Valproic acid use in psychiatry: issues in treating women of reproductive age", 23, pp.2238~ (1998)
64. Malm H, "Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility", 59, pp.6303~ (2002)
65. Okada T, "Fetal valproate syndrome with reduction deformity of limb", 37, pp.58~60 (1995)
66. major malformations, "and minor anomalies in infants born to women receiving valproic acid"
67. Felding I, "Congenital liver damage after treatment of mother with valproic acid and phenytoin"
68. Vinten J, "Neuropsychological effects of exposure to anticonvulsant medication in utero", 64, pp.949~954 (2005)
69. Cunnington M, "International Lamotrigine Pregnancy Regestry Scientific Advisory Committee: lamotrigine and the risk of malformation in pregnancy", 64, pp.955~960 (2005)
70. Mackay F, "Safety of long-term lamotrigine in epilepsy", 38, pp.8816~ (1997)
71. "Topamax product information", pp.23912396~ (2001), Montvale, NJ: Medical Economics Company, Inc
72. "Neurontin product information", pp.24582461~ (2001), Montvale, NJ: Medical Economics Company, Inc
73. Ericson A, "Delivery outcome after the use of antidepressants in early pregnancy", 55, pp.503~508 (1999)
74. McElhatton PR, "The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. a collaborative study of the European Network of Teratology Information Services (ENTIS)", 10, pp.285~294 (1996)
75. Simon GE, "Outcomes of prenatal antidepressant exposure", 159, pp.2055~2061 (2002)
76. Nulman I, "Neurodevelopment of children exposed in utero to antidepressant drugs", 336, pp.258~262 (1997)
77. Chambers CD, "Birth outcomes in pregnant women taking fluoxetine", 335, pp.1010~1015 (1996)
78. Goldstein DJ, "Effects of third trimester fluoxetine exposure on the newborn", 15, pp.417~420 (1995)
79. Kulin NA, "Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study", 279, pp.609~610 (1998)
80. Robert E, "Treatment depression in pregnancy", 335, pp.1056~1058 (1996)
81. Costei AM, "Perinatal outcome following third trimester exposure to paroxetine", 156, pp.1129~1132 (2002)
82. Nulman I, "Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study", 159, pp.1889~1895 (2002)
83. Gracious BL, "Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature and management recommendations", 6, pp.124~128 (1997)
84. Heinonen OP, "Birth defects and drugs in pregnancy", Mass Publishing Science Group; 1977
85. Einarson A, "Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study", 158, pp.1728~1730 (2001)
86. Fusun Yaris, "Newer antidepressants in pregnancy: prospective outcome of a case series Reproductive", 19, pp.235~238 (2004)
87. Djulus J, "Exposure to mirtazepine du ring pregnancy: a prospective, comparative study of birth outcomes", 67, pp.1280~1284 (2006)
88. Einarson A, "A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy", 48, pp.106~110 (2003)
89. Chun-Fai-Chan B, "Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study", 192, pp.932~936 (2005)
90. Dolovich LR, "Benzodiazepine use in pregnancy and major malformations or oral cleft metaanalysis of cohort and case-control studies", 317, pp.839~843 (1998)
91. Briggs G, "Drugs in Pregnancy and Lactation" (2002), Philadelphia: Lippincott Williams & Wilkins
92. Walstrom J, "Teratogenic effects of benzodiazepine use during pregnancy Effects of commonly used benzodiazepines on the fetus Associations between oral clefts and drugs taken during pregnancy Lack of relation of oral clefts to diazepam use during pregnancy Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study Neonatal apnea associated with maternal clonazepam therapy Obstetrical and neonatal outcome following clonazepam use during pregnancy Benzodiazepines in pregnancy analysis of 187 exposed infants drawn from a populationbased birth defects registry A possible teratogenic effect of propranolol", pp.126 39 3~131 49 7
93. Iqbal MM, "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant", 53, pp.39~49 (2002)
94. Weinstock L, "Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series", 70, pp.158~162 (1996)
95. Godet PF, "Benzodiazepines in pregnancy: analysis of 187 exposed infants drawn from a populationbased birth defects registry", 9, pp.585~ (1995)

관련 논문AI추천